Latest Healthcare News

Centuria Capital Group has outperformed its FY25 earnings guidance, reporting a 4.3% rise in operating EPS and announcing ambitious FY26 growth targets alongside the launch of Australia’s first public sovereign AI Factory.

Centuria Capital Group reported a robust FY25 with $19.7 billion in assets under management and earnings per stapled security exceeding guidance. The group is poised for strong FY26 growth, driven by stabilizing real estate markets and its pioneering sovereign AI Factory.

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.

CSL Limited posted a 14% rise in net profit for FY2025, underpinned by strong immunoglobulin sales and new product launches, while announcing plans to demerge its vaccines business, CSL Seqirus, to sharpen strategic focus.

Regal Asian Investments Limited posted a sharp 92% decline in net profit for FY25 amid volatile Asian markets but maintained a fully franked 6 cent dividend and continued its on-market share buy-back program.

Universal Biosensors has extended the due diligence period with major investor Viburnum Funds as it continues to negotiate a secured loan facility, with no binding commitment yet reached.

Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.

Rhythm Biosciences is raising up to $3.75 million through a share placement to fund the launch of its ColoSTAT® colorectal cancer diagnostic and accelerate commercialization of its geneType™ portfolio.

Cleo Diagnostics has launched a health economic study in partnership with EntityRisk and Norstella to support the U.S. market entry of its Ovarian Cancer Pre-Surgical Test, aiming to refine reimbursement strategies and accelerate commercialisation.

Apiam Animal Health has received a non-binding indicative proposal from Adamantem Capital Management to acquire the company at $0.88 per share, sparking a potential shift in ownership for the veterinary services leader.

GWA Group Limited has reported a solid FY25 financial performance with modest revenue and profit growth, alongside a dividend increase and a new $30 million share buyback program.

Lumos Diagnostics has submitted its CLIA waiver application for FebriDx® to the FDA, backed by strong clinical data and triggering significant milestone payments. Approval could expand the U.S. market opportunity fifteen-fold to over $1 billion.